ESPRESSO Study Analyzes Colorectal Dysplasia Progression and Cancer Risk in IBD Patients
A nationwide ESPRESSO study analyzed over 54,000 patients with inflammatory bowel disease (IBD) to provide estimates of colorectal dysplasia progression and colorectal cancer risk.
Key Findings
- Among IBD patients without baseline dysplasia, 2.3% developed advanced colorectal neoplasia (high-grade dysplasia or colorectal cancer) during follow-up.
- Patients with indefinite dysplasia showed a 5.3% progression to advanced neoplasia.
- Patients with low-grade dysplasia progressed to advanced neoplasia at a rate of 8.3%.
- High-grade dysplasia patients developed colorectal cancer in 40% of cases, often within one year.
The study aims to clarify the natural history of IBD-associated dysplasia and offers population-level risk estimates to inform clinical decision-making.
Expert Insight
Jordan Axelrad, MD, MPH, from the Division of Gastroenterology at NYU Grossman School of Medicine, offered his perspective.
He stated that dysplasia in IBD is not a uniform entity and that future colorectal cancer risk increases significantly by grade. Dr. Axelrad noted that high-grade lesions carry a substantial short-term colorectal cancer risk.
These findings highlight the importance of individualized surveillance and management strategies based on dysplastic findings.